Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZP-531 in Prader-Willi syndrome
2014-001670-34Phase 2Completed
- Sponsor
- Alizé Pharma
- Start
- Oct 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Prader-Willi syndrome (PWS) comparing AZP-531 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Oct 2014; status: completed.
02
Drugs
livoletide
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2014-001670-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001670-34.